v3.26.3
Allocation of Personnel Expenses
 9 Months Ended
Sep. 30, 2026
Operating Expenses [Abstract]  
Allocation of Personnel Expenses Allocation of Personnel Expenses
The Company had an average of 179 employees during the nine months ended September 30, 2026, compared to an average of 117 employees during the nine months ended September 30, 2025.
The following table summarizes the allocation of personnel expenses by function during the nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Research and Development expenses8.35.226.215.5
Sales & Marketing expenses2.10.25.30.6
General & Administrative expenses6.62.317.69.2
Total personnel expenses17.07.849.125.3
The following table summarizes the allocation of personnel expenses by nature during the nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Wages and salaries10.05.629.817.0
Social security contributions2.01.68.34.8
Expenses for pension commitments——0.10.1
Share-based payments5.00.510.93.5
Total17.07.849.125.3
Personnel expenses for the period ended September 30, 2026, increased by $23.7 million compared to the nine months ended September 30, 2025 and by $9.3 million compared to the three months ended September 30, 2025.
The increase in personnel expenses reflected the Company's continued investment in advancing VIASKIN® Peanut toward potential commercialization. Additional financing completed during 2026 enabled further organizational expansion and commercial readiness, including third-quarter interactions with the FDA, the submission of the BLA for VIASKIN® Peanut in children ages 4 through 7 on September 29, 2026, and preparation for a potential commercial launch, if approved.